Treatment Preferences and Involvement in Treatment Decision Making of Patients with Endometrial Cancer and Clinicians
Overview
Authors
Affiliations
Background: Vaginal brachytherapy (VBT) in high-intermediate-risk endometrial cancer (EC) provides a significant reduction in the risk of local cancer recurrence, but without survival benefit and with increased mucosal atrophy. Five-year local control is estimated to be similar for VBT and a watchful waiting policy (WWP), in which patients receive VBT combined with external radiation in case of a recurrence. Our aim was to assess treatment preferences of EC patients and clinicians regarding VBT and WWP, and to evaluate their preferred and perceived involvement in treatment decision making.
Methods: Interviews were held with 95 treated EC patients. The treatment trade-off method was used to assess the minimally desired benefit from VBT in local control. Patients' preferred and perceived involvement in decision making were assessed using a questionnaire. Seventy-seven clinicians completed a questionnaire assessing their minimally desired benefit and preferred involvement in decision making.
Results: Minimally desired benefit of VBT was significantly lower for patients than for clinicians (median=0 vs 8%, P<0.001), for irradiated than for non-irradiated patients (median=0 vs 6.5%, P<0.001), and for radiation oncologists than for gynaecologists (median=4 vs 13%, P<0.001). Substantial variation existed within the groups of patients and clinicians. Participants preferred the patient and clinician to share in the decision about VBT. However, irradiated patients indicated low perceived involvement in actual treatment decision making.
Conclusions: We found variations between and within patients and clinicians in minimally desired benefit from VBT. However, the recurrence risk at which patients preferred VBT was low. Our results showed that patients consider active participation in decision making essential.
van Hienen A, Offermann C, Boersma L, Jacobs M, Fijten R Clin Transl Radiat Oncol. 2024; 50:100897.
PMID: 39670055 PMC: 11636202. DOI: 10.1016/j.ctro.2024.100897.
Koning M, Lok C, Ubbink D, Aarts J BMJ Open Qual. 2024; 13(3).
PMID: 39160112 PMC: 11337712. DOI: 10.1136/bmjoq-2024-002776.
Differences between physician and patient preferences for cancer treatments: a systematic review.
Zhang M, He X, Wu J, Xie F BMC Cancer. 2023; 23(1):1126.
PMID: 37980466 PMC: 10657542. DOI: 10.1186/s12885-023-11598-4.
Keij S, de Boer J, Stiggelbout A, Bruine de Bruin W, Peters E, Moaddine S BMJ Open. 2022; 12(5):e057293.
PMID: 35613791 PMC: 9174801. DOI: 10.1136/bmjopen-2021-057293.
Kuijpers M, Veenendaal H, Engelen V, Visserman E, Noteboom E, Stiggelbout A Eur J Cancer Care (Engl). 2021; 31(1):e13534.
PMID: 34729832 PMC: 9286689. DOI: 10.1111/ecc.13534.